These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28081165)

  • 1. Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.
    Zittema D; Casteleijn NF; Bakker SJ; Boesten LS; Duit AA; Franssen CF; Gaillard CA; Gansevoort RT
    PLoS One; 2017; 12(1):e0169263. PubMed ID: 28081165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects - a CASE control study.
    Malmberg MH; Mose FH; Pedersen EB; Bech JN
    BMC Nephrol; 2020 Aug; 21(1):379. PubMed ID: 32867720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
    Casteleijn NF; Zittema D; Bakker SJ; Boertien WE; Gaillard CA; Meijer E; Spithoven EM; Struck J; Gansevoort RT
    Am J Nephrol; 2015; 41(3):248-56. PubMed ID: 25926129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Vasopressin on the Hypothalamic-Pituitary-Adrenal Axis in ADPKD Patients during V2 Receptor Antagonism.
    Heida JE; Minović I; van Faassen M; Kema IP; Boertien WE; Bakker SJL; van Beek AP; Gansevoort RT
    Am J Nephrol; 2020; 51(11):861-870. PubMed ID: 33147589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A; Lu Y; Kawano H; Horie S; Muto S
    Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion.
    Graffe CC; Bech JN; Lauridsen TG; Pedersen EB
    Am J Physiol Renal Physiol; 2012 Apr; 302(8):F917-27. PubMed ID: 22262484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered urinary excretion of aquaporin 2 in IgA nephropathy.
    Rocchetti MT; Tamma G; Lasorsa D; Suriano IV; D'Apollo A; Papale M; Mastrofrancesco L; Grandaliano G; Svelto M; Valenti G; Gesualdo L; Di Paolo S
    Eur J Endocrinol; 2011 Oct; 165(4):657-64. PubMed ID: 21824900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.
    Boertien WE; Meijer E; Li J; Bost JE; Struck J; Flessner MF; Gansevoort RT; Torres VE;
    Am J Kidney Dis; 2013 Mar; 61(3):420-9. PubMed ID: 23089511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 disruption leads to increased central vasopressin stores and impaired urine concentrating ability in mice.
    Nørregaard R; Madsen K; Hansen PB; Bie P; Thavalingam S; Frøkiær J; Jensen BL
    Am J Physiol Renal Physiol; 2011 Dec; 301(6):F1303-13. PubMed ID: 21880835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.
    Ho TA; Godefroid N; Gruzon D; Haymann JP; Maréchal C; Wang X; Serra A; Pirson Y; Devuyst O
    Kidney Int; 2012 Nov; 82(10):1121-9. PubMed ID: 22718190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.
    Amro OW; Paulus JK; Noubary F; Perrone RD
    Am J Kidney Dis; 2016 Dec; 68(6):882-891. PubMed ID: 27663039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.
    Zittema D; van den Berg E; Meijer E; Boertien WE; Muller Kobold AC; Franssen CF; de Jong PE; Bakker SJ; Navis G; Gansevoort RT
    Clin J Am Soc Nephrol; 2014 Sep; 9(9):1553-62. PubMed ID: 24993447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
    Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
    Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
    Boertien WE; Meijer E; Zittema D; van Dijk MA; Rabelink TJ; Breuning MH; Struck J; Bakker SJ; Peters DJ; de Jong PE; Gansevoort RT
    Nephrol Dial Transplant; 2012 Nov; 27(11):4131-7. PubMed ID: 22523115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentration.
    Tian Y; Serino R; Verbalis JG
    Am J Physiol Renal Physiol; 2004 Oct; 287(4):F797-805. PubMed ID: 15213068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.
    Heida JE; Gansevoort RT; Messchendorp AL; Meijer E; Casteleijn NF; Boertien WE; Zittema D;
    Clin J Am Soc Nephrol; 2021 Feb; 16(2):204-212. PubMed ID: 33504546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients.
    Zittema D; van den Brand JA; Bakker SJ; Wetzels JF; Gansevoort RT
    Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i146-i153. PubMed ID: 28057871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
    Meijer E; Bakker SJ; van der Jagt EJ; Navis G; de Jong PE; Struck J; Gansevoort RT
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):361-8. PubMed ID: 20930090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.